Bimekizumab for the treatment of psoriasis. Immunotherapy 2024 Apr;16(7):431-446
Date
03/20/2024Pubmed ID
38506262DOI
10.2217/imt-2023-0240Scopus ID
2-s2.0-85188760913 (requires institutional sign-in at Scopus site)Abstract
Psoriasis is a chronic inflammatory skin condition characterized by Th17 T cell-mediated inflammation. An emerging treatment option for psoriasis is bimekizumab, a humanized monoclonal antibody targeting cytokines IL-17A and IL-17F. Phase I trials evaluating bimekizumab reported strong safety, tolerability, and clinical efficacy with most common treatment emergent adverse events being mild to moderate in nature. Phase II trials evaluated dosing intervals, revealing that higher dosages or more frequent administration of bimekizumab resulted in minimal increases in adverse events. Phase III trials and open label extension studies demonstrated a rapid, sustained clinical response when compared with placebo and active comparators. Bimekizumab shows strong efficacy in the treatment of psoriasis and has potential in the treatment of other Th17-mediated pathologies.
Author List
Thapar M, Patel M, Gordon KAuthor
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antibodies, Monoclonal, HumanizedHumans
Psoriasis
Severity of Illness Index
Th17 Cells
Treatment Outcome
